Glaukos and Ivantis have entered into a settlement agreement to terminate a patent infringement lawsuit concerning the Hydrus microstent, according to company press releases.
Ivantis will pay Glaukos $60 million in two installments, $30 million by Dec. 31, 2021, and $30 million by Dec. 31, 2022, the Glaukos release said.
Additionally, Ivantis will pay Glaukos “a 10% ongoing royalty through April 26, 2025, based on Ivantis’ Hydrus microstent U.S. sales and any international sales supplied out of the U.S.,” according to the Glaukos release.
“Since our founding in 1998,